R. J. Bateman, Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease, New England Journal of Medicine, vol.367, issue.9, pp.795-804, 2012.
DOI : 10.1056/NEJMoa1202753

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474597/pdf

H. R. Amanatkar, B. Papagiannopoulos, and G. Grossberg, Analysis of recent failures of disease modifying therapies in Alzheimer???s disease suggesting a new methodology for future studies, Expert Review of Neurotherapeutics, vol.38, issue.1, pp.7-16, 2017.
DOI : 10.1126/scitranslmed.aaa2512

F. Hulstaert, Improved discrimination of AD patients using ??-amyloid(1-42) and tau levels in CSF, Neurology, vol.52, issue.8, pp.1555-1562, 1999.
DOI : 10.1212/WNL.52.8.1555

B. Olsson, CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis, The Lancet Neurology, vol.15, issue.7, pp.673-684, 2016.
DOI : 10.1016/S1474-4422(16)00070-3

K. Blennow and H. Zetterberg, The Application of Cerebrospinal Fluid Biomarkers in Early Diagnosis of Alzheimer Disease, Medical Clinics of North America, vol.97, issue.3, pp.369-376, 2013.
DOI : 10.1016/j.mcna.2012.12.012

A. Kadir, Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer???s disease, Brain, vol.134, issue.1, pp.301-317, 2011.
DOI : 10.1093/brain/awq349

A. D. Cohen and W. Klunk, Early detection of Alzheimer's disease using PiB and FDG PET, Neurobiology of Disease, vol.72, pp.117-122, 2014.
DOI : 10.1016/j.nbd.2014.05.001

S. Palmqvist, N. Mattsson, and O. Hansson, Cerebrospinal fluid analysis detects cerebral amyloid-?? accumulation earlier than positron emission tomography, Brain, vol.139, issue.4, pp.1226-1236, 2016.
DOI : 10.1093/brain/aww015

URL : https://academic.oup.com/brain/article-pdf/139/4/1226/17348994/aww015.pdf

N. Mattsson, Plasma tau in Alzheimer disease, Neurology, vol.87, issue.17, pp.1827-1835, 2016.
DOI : 10.1212/WNL.0000000000003246

URL : http://www.neurology.org/content/87/17/1827.full.pdf

E. Carro, Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, vol.8, pp.131-138, 2017.
DOI : 10.1016/j.dadm.2017.04.002

K. Blennow and H. Hampel, CSF markers for incipient Alzheimer's disease, The Lancet Neurology, vol.2, issue.10, pp.605-613, 2003.
DOI : 10.1016/S1474-4422(03)00530-1

O. Hansson, Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, The Lancet Neurology, vol.5, issue.3, pp.228-234, 2006.
DOI : 10.1016/S1474-4422(06)70355-6

K. Rascovsky, Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, vol.134, issue.9, pp.2456-2477, 2011.
DOI : 10.1093/brain/awr179

N. Mattsson, CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment, JAMA, vol.302, issue.4, pp.385-393, 2009.
DOI : 10.1001/jama.2009.1064

URL : http://jama.jamanetwork.com/data/journals/jama/4473/joc90069_385_393.pdf

E. Genin, APOE and Alzheimer disease: a major gene with semi-dominant inheritance, Molecular Psychiatry, vol.67, issue.9, p.903, 2011.
DOI : 10.1056/NEJMoa0809578

URL : http://www.nature.com/mp/journal/v16/n9/pdf/mp201152a.pdf

W. Jagust and L. Morrell, Positron emission tomography and magnetic resonance imaging in the diagnosis and prediction of dementia, Alzheimer's & Dementia, vol.2, issue.1, pp.36-42, 2004.
DOI : 10.1016/j.jalz.2005.11.002

M. P. Laakso, Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study, Neurology, vol.46, issue.3, pp.678-681, 1996.
DOI : 10.1212/WNL.46.3.678

G. B. Frisoni, Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease, Neurology, vol.52, issue.1, pp.91-100, 1999.
DOI : 10.1212/WNL.52.1.91

G. B. Frisoni, Detection of grey matter loss in mild Alzheimer's disease with voxel based morphometry, Journal of Neurology, Neurosurgery & Psychiatry, vol.73, issue.6, pp.657-664, 2002.
DOI : 10.1136/jnnp.73.6.657

P. T. Nelson, Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature, Journal of Neuropathology & Experimental Neurology, vol.71, issue.5, pp.362-381, 2012.
DOI : 10.1097/NEN.0b013e31825018f7

D. R. Thal, U. Rüb, M. Orantes, and H. Braak, Phases of A??-deposition in the human brain and its relevance for the development of AD, Neurology, vol.58, issue.12, pp.1791-1800, 2002.
DOI : 10.1212/WNL.58.12.1791

M. N. Sabbagh, Functional, Global and Cognitive Decline Correlates to Accumulation of Alzheimers Pathology in MCI and AD, Current Alzheimer Research, vol.7, issue.4, p.280, 2010.
DOI : 10.2174/156720510791162340

H. Braak and E. Braak, Neuropathological stageing of Alzheimer-related changes, Acta Neuropathologica, vol.80, issue.4, pp.239-259, 1991.
DOI : 10.1007/978-3-642-70644-8_2

A. Delacourte, The biochemical pathway of neurofibrillary degeneration in aging and

K. Blennow, M. J. De-leon, and H. Zetterberg, Alzheimer's disease, The Lancet, vol.368, issue.9533, pp.387-403, 2006.
DOI : 10.1016/S0140-6736(06)69113-7

URL : https://hal.archives-ouvertes.fr/hal-01098836

R. Rademakers and A. Rovelet-lecrux, Recent insights into the molecular genetics of dementia, Trends in Neurosciences, vol.32, issue.8, p.451, 2009.
DOI : 10.1016/j.tins.2009.05.005

G. Nicolas, Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons, European Journal of Human Genetics, vol.39, issue.5, p.710, 2016.
DOI : 10.1007/s00415-013-7160-3

URL : https://hal.archives-ouvertes.fr/hal-01431285

D. Harold, Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, Nature Genetics, vol.34, issue.10, p.1088, 2009.
DOI : 10.1212/WNL.56.1.127

URL : http://www.nature.com/ng/journal/v45/n6/pdf/ng0613-712a.pdf

T. Jonsson, Associated with the Risk of Alzheimer's Disease, New England Journal of Medicine, vol.368, issue.2, 2013.
DOI : 10.1056/NEJMoa1211103

J. Lambert, The CALHM1 P86L polymorphism is a genetic modifier of age at onset in

D. Wallon, The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers, J. Alzheimers Dis, vol.30, pp.847-856, 2012.

A. J. Larner and M. Doran, Genotype-phenotype relationships of presenilin-1 mutations in

H. Karlstrom, Variable phenotype of Alzheimer's disease with spastic paraparesis, J

M. Anheim, Ataxic variant of Alzheimer's disease caused by Pro117Ala PSEN1 mutation, Journal of Neurology, Neurosurgery & Psychiatry, vol.78, issue.12
DOI : 10.1136/jnnp.2007.123026

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095586/pdf

D. M. Mann, S. M. Pickering-brown, A. Takeuchi, T. Iwatsubo, and . Group, Amyloid Angiopathy and Variability in Amyloid ?? Deposition Is Determined by Mutation Position in Presenilin-1-Linked Alzheimer???s Disease, The American Journal of Pathology, vol.158, issue.6, p.2165, 2001.
DOI : 10.1016/S0002-9440(10)64688-3

S. Jayadev, Alzheimer???s disease phenotypes and genotypes associated with mutations in presenilin 2, Brain, vol.133, issue.4, p.1143, 2010.
DOI : 10.1093/brain/awq033

J. Hardy and D. Allsop, Amyloid deposition as the central event in the aetiology of Alzheimer's disease, Trends in Pharmacological Sciences, vol.12, pp.383-388, 1991.
DOI : 10.1016/0165-6147(91)90609-V

M. S. Wolfe and S. Y. Guénette, APP at a glance, Journal of Cell Science, vol.120, issue.18, pp.3157-3161, 2007.
DOI : 10.1242/jcs.03481

D. Fede and G. , A Recessive Mutation in the APP Gene with Dominant-Negative Effect on Amyloidogenesis, Science, vol.278, issue.16, pp.1473-1477, 2009.
DOI : 10.1074/jbc.M211976200

A. Rovelet-lecrux, APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy, Nature Genetics, vol.302, issue.1, pp.24-26, 2006.
DOI : 10.1212/WNL.56.7.979

C. Pottier, Amyloid-? protein precursor gene expression in alzheimer's disease and other conditions, J. Alzheimers Dis, vol.28, pp.561-566, 2012.

K. Sleegers, APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy, Brain, vol.129, issue.11, pp.2977-2983, 2006.
DOI : 10.1093/brain/awl203

I. T. Coyle-gilchrist, Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes, Neurology, vol.86, issue.18, pp.1736-1743, 2016.
DOI : 10.1212/WNL.0000000000002638

URL : http://www.neurology.org/content/86/18/1736.full.pdf

J. Bang, S. Spina, and B. L. Miller, Frontotemporal dementia, The Lancet, vol.386, issue.10004, pp.1672-1682, 2015.
DOI : 10.1016/S0140-6736(15)00461-4

R. T. Vieira, Epidemiology of early-onset dementia: a review of the literature, Clinical Practice & Epidemiology in Mental Health, vol.9, issue.1, pp.88-95, 2013.
DOI : 10.2174/1745017901309010088

J. D. Rohrer, The heritability and genetics of frontotemporal lobar degeneration, Neurology, vol.73, issue.18
DOI : 10.1212/WNL.0b013e3181bf997a

P. H. Robert, V. Lafont, J. S. Snowden, and F. Lebert, Diagnostic criteria for fronto-temporal lobe degeneration], Encephale, vol.25, pp.612-621, 1999.

D. Neary, Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria, Neurology, vol.51, issue.6, pp.1546-1554, 1998.
DOI : 10.1212/WNL.51.6.1546

J. L. Whitwell, Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics, Brain, vol.135, issue.3, pp.794-806, 2012.
DOI : 10.1093/brain/aws001

URL : https://academic.oup.com/brain/article-pdf/135/3/794/5504348/aws001.pdf

J. S. Snowden, D. Neary, and D. M. Mann, Frontotemporal dementia, The British Journal of Psychiatry, vol.180, issue.2, pp.140-143, 2002.
DOI : 10.1192/bjp.180.2.140

G. U. Höglinger, Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria, Movement Disorders, vol.31, issue.Suppl 2, pp.853-864, 2017.
DOI : 10.1523/JNEUROSCI.2600-10.2011

J. J. Hauw, Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy), Neurology, vol.44, issue.11, pp.2015-2019, 1994.
DOI : 10.1212/WNL.44.11.2015

A. L. Boxer, Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches, The Lancet Neurology, vol.16, issue.7, pp.552-563, 2017.
DOI : 10.1016/S1474-4422(17)30157-6

K. Sakurai, Beyond the midbrain atrophy: wide spectrum of structural MRI finding in cases of pathologically proven progressive supranuclear palsy, Neuroradiology, vol.252, issue.Pt 6, pp.431-443, 2017.
DOI : 10.1007/s00415-005-0791-2

L. Ber and I. , Genetics of frontotemporal lobar degeneration: an up-date and diagnosis algorithm

I. R. Mackenzie and M. Neumann, Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies, Journal of Neurochemistry, vol.110, pp.54-70, 2016.
DOI : 10.1073/pnas.1315438110

X. Pan and X. Chen, Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review, Translational Neurodegeneration, vol.2, issue.1, p.8, 2013.
DOI : 10.1002/humu.20785

P. E. Ash, Unconventional Translation of C9ORF72 GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/ALS, Neuron, vol.77, issue.4, pp.639-646, 2013.
DOI : 10.1016/j.neuron.2013.02.004

B. F. Boeve, Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72, Brain, vol.135, issue.3, pp.765-783, 2012.
DOI : 10.1093/brain/aws004

N. A. Murphy, Age-related penetrance of the C9orf72 repeat expansion, Scientific Reports, vol.34, issue.1, p.2116, 2017.
DOI : 10.3233/JAD-121456

M. Cruts, I. Gijselinck, T. Van-langenhove, J. Van-der-zee, and C. Van-broeckhoven, Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum, Trends in Neurosciences, vol.36, issue.8, pp.450-459, 2013.
DOI : 10.1016/j.tins.2013.04.010

J. S. Snowden, Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations, Brain, vol.135, issue.3, pp.693-708, 2012.
DOI : 10.1093/brain/awr355

M. Carecchio, Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease, Journal of the Neurological Sciences, vol.287, issue.1-2, pp.291-293, 2009.
DOI : 10.1016/j.jns.2009.07.011

D. A. Olszewska, R. Lonergan, E. M. Fallon, and T. Lynch, Genetics of Frontotemporal Dementia, Current Neurology and Neuroscience Reports, vol.130, issue.Pt 3, 2016.
DOI : 10.1093/brain/awl367

J. O. Johnson, Exome sequencing reveals VCP mutations as a cause of familial ALS

O. V. Forlenza, Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, vol.1, issue.4, pp.455-463, 2015.
DOI : 10.1016/j.dadm.2015.09.003

S. Lehmann, Impact of harmonization of collection tubes on Alzheimer's disease diagnosis, Alzheimer's & Dementia, vol.10, issue.5, pp.390-394, 2014.
DOI : 10.1016/j.jalz.2013.06.008

A. M. Fagan, in humans, Annals of Neurology, vol.111, issue.3, pp.512-519, 2006.
DOI : 10.1172/JCI200317527

T. Tapiola, Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of

K. Kanemaru, N. Kameda, and H. Yamanouchi, Decreased CSF amyloid ??42 and normal tau levels in dementia with Lewy bodies, Neurology, vol.54, issue.9, pp.1875-1876, 2000.
DOI : 10.1212/WNL.54.9.1875

M. Sjögren, CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging, J Neural Transm, vol.107, pp.563-579, 2000.

T. Sunderland, Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease, JAMA, vol.289, pp.2094-2103, 2003.

C. Ritchie, ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI), Cochrane Database Syst Rev, vol.3, p.10803, 2017.

B. Dubois, Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, The Lancet Neurology, vol.13, issue.6
DOI : 10.1016/S1474-4422(14)70090-0

A. Rivero-santana, Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer???s Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors, Journal of Alzheimer's Disease, vol.42, issue.Suppl 1, pp.625-644, 2016.
DOI : 10.1159/000448394

C. Hesse, Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neuroscience Letters, vol.297, issue.3, pp.187-190, 2001.
DOI : 10.1016/S0304-3940(00)01697-9

S. Neselius, CSF-Biomarkers in Olympic Boxing: Diagnosis and Effects of Repetitive Head Trauma, PLoS ONE, vol.41, issue.5, p.33606, 2012.
DOI : 10.1371/journal.pone.0033606.t003

H. Hampel, Total and phosphorylated tau protein as biological markers of Alzheimer???s disease, Experimental Gerontology, vol.45, issue.1, pp.30-40, 2010.
DOI : 10.1016/j.exger.2009.10.010

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815003/pdf

H. Hampel, Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer Disease, Archives of General Psychiatry, vol.61, issue.1, pp.95-102, 2004.
DOI : 10.1001/archpsyc.61.1.95

S. Lehmann, A diagnostic scale for Alzheimer???s disease based on cerebrospinal fluid biomarker profiles, Alzheimer's Research & Therapy, vol.6, issue.3, p.38, 2014.
DOI : 10.1186/alzrt267

D. Riva and V. , Analysis of Combined CSF Biomarkers in AD Diagnosis, Clinical Laboratory, vol.60, issue.04/2014, pp.629-634, 2014.
DOI : 10.7754/Clin.Lab.2013.130440

P. Buchhave, Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease, PLoS ONE, vol.4, issue.7
DOI : 10.1371/journal.pone.0006294.t002

D. J. Irwin, J. Q. Trojanowski, and M. Grossman, Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease, Frontiers in Aging Neuroscience, vol.5, 2013.
DOI : 10.3389/fnagi.2013.00006

L. M. Shaw, Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI, Acta Neuropathologica, vol.46, issue.5, pp.597-609, 2011.
DOI : 10.1258/acb.2009.008232

H. Bian, CSF biomarkers in frontotemporal lobar degeneration with known pathology, Neurology, vol.70, issue.Issue 19, Part 2
DOI : 10.1212/01.wnl.0000311445.21321.fc

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707002/pdf

H. Brunnström, Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses, Alzheimer's & Dementia, vol.6, issue.2, pp.104-109, 2010.
DOI : 10.1016/j.jalz.2009.12.005

D. J. Irwin, Comparison of Cerebrospinal Fluid Levels of Tau and A?? 1-42 in Alzheimer Disease and Frontotemporal Degeneration Using 2 Analytical Platforms, Archives of Neurology, vol.69, issue.8, pp.1018-1025, 2012.
DOI : 10.1001/archneurol.2012.26

J. L. Seeburger, Cerebrospinal fluid biomarkers distinguish postmortem-confirmed

P. Steinacker, TDP-43 in Cerebrospinal Fluid of Patients With Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis, Archives of Neurology, vol.65, issue.11, pp.1481-1487, 2008.
DOI : 10.1001/archneur.65.11.1481

R. Ghidoni, L. Benussi, M. Glionna, M. Franzoni, and G. Binetti, Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration, Neurology, vol.71, issue.16, pp.1235-1239, 2008.
DOI : 10.1212/01.wnl.0000325058.10218.fc

M. Ewers, CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study, Alzheimer's & Dementia, vol.11, issue.11, pp.1306-1315, 2015.
DOI : 10.1016/j.jalz.2014.12.006

N. Mattsson, Age and diagnostic performance of Alzheimer disease CSF biomarkers, Neurology, vol.78, issue.7
DOI : 10.1212/WNL.0b013e3182477eed

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280049/pdf

N. S. Schoonenboom, Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort, Neurology, vol.78, issue.1, pp.47-54, 2012.
DOI : 10.1212/WNL.0b013e31823ed0f0

P. E. Spies, A prediction model to calculate probability of Alzheimer???s disease using cerebrospinal fluid biomarkers, Alzheimer's & Dementia, vol.9, issue.3, pp.262-268, 2013.
DOI : 10.1016/j.jalz.2012.01.010

C. Mulder, Amyloid-??(1-42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease, Clinical Chemistry, vol.56, issue.2, pp.248-253, 2010.
DOI : 10.1373/clinchem.2009.130518

F. H. Duits, The cerebrospinal fluid ???Alzheimer profile???: Easily said, but what does it mean?, Alzheimer's & Dementia, vol.10, issue.6, pp.713-723, 2014.
DOI : 10.1016/j.jalz.2013.12.023

A. Fourier, Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability, Clinica Chimica Acta, vol.449, pp.9-15, 2015.
DOI : 10.1016/j.cca.2015.05.024

M. Bjerke, Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid, International Journal of Alzheimer's Disease, vol.309, issue.6955, 2010.
DOI : 10.1258/acb.2009.008232

URL : https://doi.org/10.4061/2010/986310

J. B. Toledo, CSF biomarkers cutoffs: the importance of coincident neuropathological diseases, Acta Neuropathologica, vol.7, issue.4, pp.23-35, 2012.
DOI : 10.1016/j.jalz.2010.08.233

M. Grossman, Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease, Annals of Neurology, vol.160, issue.5, pp.721-729, 2005.
DOI : 10.1016/S0002-9440(10)61154-6

C. M. Clark, Cerebrospinal Fluid Tau and ??-Amyloid, Archives of Neurology, vol.60, issue.12, pp.1696-1702, 2003.
DOI : 10.1001/archneur.60.12.1696

URL : http://archneur.jamanetwork.com/data/journals/neur/13548/noc30071.pdf

S. Engelborghs, Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia, Neurobiology of Aging, vol.29, issue.8, pp.1143-1159, 2008.
DOI : 10.1016/j.neurobiolaging.2007.02.016

H. Lanoiselée, APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases, PLOS Medicine, vol.21, issue.6, p.1002270, 2017.
DOI : 10.1371/journal.pmed.1002270.s002

I. R. Mackenzie, Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update, Acta Neuropathologica, vol.323, issue.1, pp.1-4, 2010.
DOI : 10.1007/s00401-004-0882-7

S. Lehmann, Preanalytical guidelines for clinical proteomics investigation of biological fluids], Ann. Biol. Clin. (Paris), vol.67, pp.629-639, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00444355

C. E. Teunissen, N. A. Verwey, M. I. Kester, K. Van-uffelen, and M. A. Blankenstein, Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid ?((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop, Int J Alzheimers Dis, 2010.

K. Hajian-tilaki, Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation, Caspian J Intern Med, vol.4, pp.627-635, 2013.

C. Marelli, Late-onset behavioral variant of frontotemporal lobar degeneration??versus Alzheimer's disease: Interest of cerebrospinal fluid??biomarker??ratios, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, vol.1, issue.3, pp.371-379, 2015.
DOI : 10.1016/j.dadm.2015.06.004

A. Rivero-santana, Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer???s Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors, Journal of Alzheimer's Disease, vol.42, issue.Suppl 1, pp.625-644, 2016.
DOI : 10.1159/000448394

K. Koopman, Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P, Neurochemistry International, vol.55, issue.4, pp.214-218, 2009.
DOI : 10.1016/j.neuint.2009.02.017

L. Grangeon, Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein, Journal of Alzheimer's Disease, vol.6, issue.3, pp.905-913, 2016.
DOI : 10.1186/s13195-014-0072-3

E. G. Vijverberg, Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric??disorders, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, vol.7, pp.99-106, 2017.
DOI : 10.1016/j.dadm.2017.01.009

URL : https://doi.org/10.1016/j.dadm.2017.01.009

C. L. Sutphen, Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age, JAMA Neurology, vol.72, issue.9, pp.1029-1042, 2015.
DOI : 10.1001/jamaneurol.2015.1285

URL : http://archneur.jamanetwork.com/data/journals/neur/934389/noi150034.pdf

M. Sjögren, Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values, Clin. Chem, vol.47, pp.1776-1781, 2001.

J. D. Rohrer, Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis, The Lancet Neurology, vol.14, issue.3, pp.253-262, 2015.
DOI : 10.1016/S1474-4422(14)70324-2

D. C. Ryman, Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis, Neurology, vol.83, issue.3, pp.253-260, 2014.
DOI : 10.1212/WNL.0000000000000596

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117367/pdf

A. M. Fagan, Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease, Science Translational Medicine, vol.53, issue.3, pp.226-256, 2014.
DOI : 10.2307/2533558

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038930/pdf

S. Lista, Biomarkers in Sporadic and Familial Alzheimer???s Disease, Journal of Alzheimer's Disease, vol.6, issue.102, pp.291-317, 2015.
DOI : 10.1126/scitranslmed.3007941

A. M. Fagan and D. M. Holtzman, Cerebrospinal fluid biomarkers of Alzheimer???s disease, Biomarkers in Medicine, vol.27, issue.1, pp.51-63, 2010.
DOI : 10.1002/ana.21623

E. Stomrud, L. Minthon, H. Zetterberg, K. Blennow, and O. Hansson, Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, vol.1, issue.4, pp.403-411, 2015.
DOI : 10.1016/j.dadm.2015.09.002

F. H. Bouwman, Longitudinal changes of CSF biomarkers in memory clinic patients, Neurology, vol.69, issue.10, pp.1006-1011, 2007.
DOI : 10.1212/01.wnl.0000271375.37131.04

E. Stomrud, Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults, Archives of Neurology, vol.67, issue.2, pp.217-223, 2010.
DOI : 10.1001/archneurol.2009.316

C. R. Jack, Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers, The Lancet Neurology, vol.12, issue.2, pp.207-216, 2013.
DOI : 10.1016/S1474-4422(12)70291-0

T. T. Seppälä, Longitudinal changes of CSF biomarkers in Alzheimer's disease, J. Alzheimers Dis, vol.25, pp.583-594, 2011.

V. Velickaite, Cognitive function in very old men does not correlate to biomarkers of Alzheimer???s disease, BMC Geriatrics, vol.9, issue.1, p.208, 2017.
DOI : 10.1016/j.jalz.2012.11.011

A. Papegaey, Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutation, Acta Neuropathologica Communications, vol.10, issue.1, 2016.
DOI : 10.1002/glia.22453

URL : https://hal.archives-ouvertes.fr/inserm-01346896

J. I. Vélez, APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer???s disease, Molecular Psychiatry, vol.37, issue.7, pp.916-924, 2016.
DOI : 10.1016/j.neubiorev.2013.10.010

D. Mungas, R. Tractenberg, J. A. Schneider, P. K. Crane, and D. A. Bennett, A 2-process model for neuropathology of Alzheimer's disease, Neurobiology of Aging, vol.35, issue.2, pp.301-308, 2014.
DOI : 10.1016/j.neurobiolaging.2013.08.007

J. B. Toledo, Alzheimer???s disease cerebrospinal fluid biomarker in cognitively normal subjects, Brain, vol.138, issue.9, pp.2701-2715, 2015.
DOI : 10.1093/brain/awv199

URL : https://academic.oup.com/brain/article-pdf/138/9/2701/13800509/awv199.pdf

J. B. Toledo, Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 ??-Amyloid Measures Across the Spectrum of Alzheimer Disease, JAMA Neurology, vol.72, issue.5, pp.571-581, 2015.
DOI : 10.1001/jamaneurol.2014.4829

A. Gabelle, French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study, J. Alzheimers Dis, vol.34, pp.297-305, 2008.

A. Perret-liaudet, Cerebrospinal Fluid Collection Tubes: A Critical Issue for Alzheimer Disease Diagnosis, Clinical Chemistry, vol.58, issue.4, pp.787-789, 2012.
DOI : 10.1373/clinchem.2011.178368

URL : https://hal.archives-ouvertes.fr/hal-00965203

N. Mattsson, Clinical validity of cerebrospinal fluid A??42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework, Neurobiology of Aging, vol.52, pp.196-213, 2017.
DOI : 10.1016/j.neurobiolaging.2016.02.034

A. Gabelle, Decreased sA?PP?, A?38, and A?40 cerebrospinal fluid levels in frontotemporal dementia, J. Alzheimers Dis, vol.26, pp.553-563, 2011.

J. M. Ringman, Cerebrospinal Fluid Biomarkers and Proximity to Diagnosis in Preclinical Familial Alzheimer's Disease, Dementia and Geriatric Cognitive Disorders, vol.2, issue.1, pp.1-5, 2012.
DOI : 10.1038/nm0896-864

G. Nicolas, SORL1 rare variants: a major risk factor for familial early-onset Alzheimer???s disease, Molecular Psychiatry, vol.21, issue.6, pp.831-836, 2016.
DOI : 10.1038/nature12975